Given the limited evidence from RCTs with generally small sample sizes [5–7], the beneficial associations of genetic proxies for ACE inhibitors and CCBs in comparison with other classes of antihypertensives provide support for the current clinical guidelines on the treatment of hypertension when it occurs with chronic kidney disease. This evidence concerns the gene ACE and chronic kidney disease.